FDA warned kdc/one Chatsworth of CGMP violations in OTC drugs, including missing carcinogen testing and storage temperature failures.
What happened
FDA inspected the Chatsworth, CA drug manufacturing facility from March 31 to April 3, 2026. FDA found the company released OTC drugs without appropriate final-product and stability testing, including no testing for a known carcinogenic degradant; did not adequately investigate viscosity out-of-specification results; and stored a batch above labeled and internal temperature limits. FDA reviewed the company’s April 24, 2026 response and found it inadequate.
What FDA found
The company released OTC drug batches without appropriate final-product testing and without an adequate stability program.
21 CFR 211.165(a) and 211.166(a)The company did not test OTC products for a known carcinogenic degradant before release or during stability testing, despite known degradation pathways and a Canadian recall of products made with the same formulation.
21 CFR 211.165(a) and 211.166(a)The company did not thoroughly investigate viscosity out-of-specification results from stability testing of distributed OTC drugs.
21 CFR 211.192The company stored a released OTC batch at temperatures above its labeled storage conditions and internal protocol and did not include storage conditions on certificates of analysis.
21 CFR 211.142(b)FDA said the quality unit was not able to fully exercise its authority and/or responsibilities.
What FDA wants
FDA tells the company to correct the violations and provide detailed testing results, risk assessments, retrospective reviews, corrective action plans, and stability and laboratory remediation plans. The company must send its written response within 15 business days of receipt.
Who should pay attention
- brands whose OTC products are made at this facility
- companies selling OTC drugs with similar formulations
- U.S. distributors and retailers holding affected OTC batches
This is a summary. Read the original letter on fda.gov.